类风湿关节炎中JAK抑制剂与非黑色素瘤皮肤癌风险:与IL-6受体抑制剂比较的国家队列研究
该研究基于英国风湿病学会生物制剂注册与全国癌症登记数据,纳入3985例首次启用JAK抑制剂或IL-6受体抑制剂的类风湿关节炎患者,比较非黑色素瘤皮肤癌风险。主要分析显示JAK抑制剂相对IL-6受体抑制剂的IPTW风险比为1.64(95%CI 0.85-3.17),绝对率差为每1000人年3.3例事件,差异未达统计学显著。
要点
- JAK抑制剂较IL-6受体抑制剂的非黑色素瘤皮肤癌风险比为1.64(95%CI 0.85-3.17),无统计学显著性。
- 绝对率差为每1000人年3.3例事件,约每307例启用JAK抑制剂而非IL-6受体抑制剂并观察一年者增加1例事件。
- 接受治疗分析中JAK抑制剂与IL-6受体抑制剂的IPTW风险比为1.82(95%CI 0.84-3.96)。
核心结论
- 启用JAK抑制剂与非黑色素瘤皮肤癌风险较IL-6受体抑制剂有临床幅度较小、可能偏高的关联,但在约3.3年观察期内未达统计学显著。
研究设计与样本
- 研究使用英国风湿病学会类风湿关节炎生物制剂注册库与全国癌症登记和分析服务链接的数据。
- 纳入首次启用JAK抑制剂或IL-6受体抑制剂且既往未暴露于对照类药物的人群,主要分析为曾暴露模型并排除治疗启动后前90天。
- 采用Cox比例风险模型结合逆概率治疗加权估计风险比,次要分析为接受治疗分析。
主要发现
- 主要分析共纳入3985例类风湿关节炎患者,记录到116例首次非黑色素瘤皮肤癌。
- JAK抑制剂对比IL-6受体抑制剂的IPTW风险比为1.64(95%CI 0.85-3.17)。
- IPTW绝对率差为每1000人年3.3例事件,相当于每307例启用JAK抑制剂而非IL-6受体抑制剂并观察一年者约增加1例非黑色素瘤皮肤癌事件。
- 接受治疗分析中,IL-6受体抑制剂组和JAK抑制剂组分别发生32例和19例非黑色素瘤皮肤癌事件,IPTW风险比为1.82(95%CI 0.84-3.96)。
临床怎么用
- 风湿科医生和患者在考虑治疗选择时,应将非黑色素瘤皮肤癌的潜在风险与疾病控制的获益进行权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin-6 receptor inhibitors (IL-6Ri). METHODS: This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the National Cancer Registration and Analysis Service. People with RA initiating first JAKi or IL-6Ri without prior exposure to the comparator class were included. The primary analysis was ever-exposed model with first 90 days after treatment initiation excluded. Cox proportional hazards models estimated hazard ratios (HRs) with inverse probability of treatment weighting (IPTW) to adjust for confounding. Secondary analysis was receiving-treatment analysis. RESULTS: A total of 3,985 people with RA were included in primary analysis, with 116 first-ever NMSC recorded. The IPTW HR for JAKi versus IL-6Ri was 1.64 (95% confidence interval [CI] 0.85-3.17). The IPT-weighted absolute rate difference was 3.3 events per 1,000 person-years with JAKi versus IL-6Ri, which is around one additional NMSC event for every 307 patients who initiated JAKi rather than IL-6Ri and were observed for one year. In receiving-treatment analysis, 32 and 19 NMSC events occurred among patients actively receiving IL-6Ri and JAKi, with IPTW HR of 1.82 (95% CI 0.84-3.96). CONCLUSION: Initiation of JAKi was associated with a clinically small, plausibly higher NMSC risk than IL-6Ri, although not statistically significant over 3.3 years. Rheumatologists and patients should weigh the potential risk of NMSC against the benefits of disease control when considering treatment choices.
引用
- Tian Z, Kearsley-Fleet L, Zhao SS, et al. Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin-6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study. Arthritis Rheumatol. 2026. PMID: 42421604. doi:10.1002/art.70272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。